Abstract: The present invention relates to an asymmetric flow field-flow fractionation device (1) configured to separate a sample (8) of particles (12) dispersed in a liquid mobile phase (11), the device including a fractionation microchannel (2) comprising a sample inlet, a sample outlet, an auxiliary microchannel (3) comprising an auxiliary outlet, a semipermeable membrane (10) separating the fractionation microchannel (2) and the auxiliary microchannel (3), said membrane being permeable to liquid and being configured to maintain the particles (12) in said fractionation microchannel (2), the fractionation microchannel (2) being superimposed on the auxiliary microchannel (3), wherein the device (1) comprises two layers (19), each layer being with a microfabricated recess (14) which thickness (t) is less than 100IJm, the membrane (10) being mechanically held in between the two layers (19), the recesses (14) respectively defining the fractionation microchannel (2) and the auxiliary microchannel (3) on each side of the m

Abstract: The invention relates to a capped cyclodextrin-hydrophobic moiety conjugate, to a supramolecular polymer formed of capped cyclodextrin-hydrophobic moiety conjugates according to the invention and to a siRNA-cyclodextrin complex comprising a supramolecular polymer according to the invention. The invention also relates to a method for manufacturing the capped cyclodextrin-hydrophobic moiety conjugate, the supramolecular polymer, the siRNA-cyclodextrin complex according to the invention. The capped cyclodextrin-hydrophobic moiety conjugate of the invention comprises a capped cyclodextrin group and at least one hydrophobic moiety bound by a first linker to one of the carbon atoms of the cap. The invention can be used for various applications in particular in the pharmaceutical field.

Abstract: This oscillator comprises: a source generating an incident optical wave at a pulsation frequency ?; an optomechanical resonator, having optical resonances at the pulsation frequency ? and mechanical resonances at a frequency f1 and generating, from the incident optical wave, emergent optical waves at the pulsation frequencies ? and ??2?f1, and an acoustic wave at frequency f1; and, a photodiode delivering a useful signal at frequency f1 from the emergent waves. This oscillator further comprises: an acoustic propagation means for propagating the acoustic wave over a distance in order to produce a delayed acoustic wave; a means for converting the delayed acoustic wave into a delay signal at the frequency f1; and, a control loop, processing the delay signal in order to obtain a control signal applied to the source.

Abstract: The invention relates to a non-invasive process for evaluating the quality of one or more dense connective tissue(s) in a patient, comprising the following steps: a) Analyzing the profile of the microrelief of a cutaneous replica of a portion of the skin of said patient by at least one of the following step: a1. visually assessing on picture(s) of said cutaneous replica the line shape and the anisotropy of the lines; and/or a2. Determining, on picture(s) of said cutaneous replica, the roughness index of the microrelief with an optical sensor, b) identifying cutaneous replica of “stage 1”, representative of healthy skins, and cutaneous replica of “stage 2” representative of altered skins, a cutaneous replica of stage 2 being indicative of low quality of the one or more dense connective tissue(s) in the patients body.

Abstract: In most cases, cancer chemotherapy and immunotherapy fail to yield durable responses, and complete and permanent regression of established tumors are rare. Here the inventors show that so-called caloric restriction mimetics (CRMs), which are natural or synthetic compounds that pharmacologically mimic the effects of fasting or caloric restriction, can be used to enhance the probability of cancer cure. The administration of several chemically distinct CRMs (such as hydroxycitrate, lipoic acid and the natural polyamine spermidine) led to the complete regression and the induction of protective anticancer immune responses in mouse models. This effect was achieved when CRMs were combined with chemotherapy and immunotherapy targeting the immune checkpoint molecules CTLA-4 and/or PD-1. Hence, caloric restriction and CRMs can be used to sensitize cancers to chemo-immunotherapy.

Abstract: This method for generating an indicator of the state of a patient in coma includes: generating at least one auditory stimulation by generating a sequence of auditory stimuli, the sequence producing evoked potentials in the patient; acquiring a first electroencephalographic signal produced by patient from at least one electrode; estimating at least one pair of values corresponding to a first parameter and a second parameter extracted from the first acquired signal, including estimating a first pair of values such that calculating the first parameter includes an estimation of the amplitude variance of the first signal within a predefined time window and the calculation of the second parameter includes an estimation of the correlation of two segments of the first signal; generating a state indicator for the or each pair of values of the first and second parameters, the values defining coordinates of a point in a reference base.

Abstract: The present invention relates to an in vitro method for identifying and/or characterizing one or more mutations in a hotspot mutation sequence of at least one ESR1 target fragment from a DNA sample, said method comprising subjecting the DNA sample to a drop-off digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: a pair of primers suitable for amplifying an ESR1 target fragment; an oligonucleotide reference (REF) hydrolysis probe, labeled with a fluorophore, wherein said REF oligonucleotide probe is complementary to a wild-type sequence of the target fragment located outside of the hotspot mutation sequence; an oligonucleotide hotspot (HOTSPOT) hydrolysis probe, labeled with another fluorophore, wherein said oligonucleotide HOTSPOT probe is complementary to a wild-type sequence of the hotspot mutation sequence of the target DNA fragment.

Abstract: A method for performing spacetime-constrained oblivious transfer between various laboratories of a first party A and various laboratories of a second party B. The method includes providing the spacetime-constrained oblivious transfer to satisfy various conditions. The method further includes encoding, by the laboratories of the first party A, various messages in a quantum state selected from various non-orthogonal quantum states. The method further includes transmitting, by the laboratories of the first party A, the quantum state to a first laboratory of the second party B. The method further includes applying, by the first laboratory of the second party B, a quantum measurement on the quantum state to obtain a classical measurement outcome. The method further includes transmitting, by the first laboratory of the second party B, the classical measurement outcome to the laboratories of the second party B.

Abstract: The present invention relates to an in vitro method for testing the cytotoxicity of a candidate compound for living target cells, said method relying on the detection of the massive release of a cytosolic luminescent enzyme in the supernatant of the cells once they have been voluntarily permeabilized. The detection of this release is rapid and reproducible. More precisely, the method of the invention comprises the steps: a) contacting, with a candidate compound, living target cells that constitutively express in their cytosol a luminescent enzyme, b) isolating the supernatant of the coculture of step a) in a second recipient, c) adding in said second recipient the substrate of said luminescent enzyme, and d) measuring the luminescence emitted in said second recipient. The cytotoxicity of said candidate compound is then proportional to the increase in luminescence measured in step d).

Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydro-carbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.

Abstract: The invention proposes a new method for monitoring a health event in a mammal, comprising detecting at least one abnormal value within a series of values related to at least one biomarker, based on appropriate Z-scores.

Abstract: The present invention relates to humanized anti-human GPVI antibodies and uses thereof.

Abstract: The present invention relates to a single-lumen vascular catheter to be inserted into a blood flow channel for the injection of a product by the venous or arterial route, comprising a tube having a hollow longitudinal body with a lumen, the lumen extending along the full length of the tube and being intended to permit the injection of a given volume of product at a prescribed flow rate the tube having lateral orifices which are of substantially identical size and are arranged in the longitudinal body substantially symmetrically about the longitudinal axis, near a distal end of the tube, an end surface at the distal end of the tube reducing a total surface area of the lumen starting from the distal end of the tube.

Abstract: The present invention relates to various soluble forms of CD31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of CD31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed CD31 and the use of such methods as a diagnostic tool.

Abstract: Disclosed is a lithography process on a sample with at least one emitter, the process including: putting at least one layer of resist above the sample; exciting one selected emitter with light through the at least one layer of resist; detecting light emitted by the excited selected emitter and determining a position of the selected emitter; and curing with a light beam a part of the at least one layer of resist above the position of the selected emitter, the light beam being a shaped light beam having a cross-section, this cross-section having a central part, an intermediate part surrounding the central part and a border part surrounding the intermediate part, the intensity of the shaped light beam on the at least one layer of resist reaching a maximum at the intermediate part.

Abstract: Probenecid or a pharmaceutical acceptable salt thereof for use in the treatment of a neurological disorder in a subject in need thereof, wherein administration of probenecid or a pharmaceutical acceptable salt thereof controls clinical or electrographic seizures in the subject. Preferably, the neurological disorder is an epileptic disease, disorder or condition.

Abstract: A compound of general formula (I): in which X represents O, S, NH or an N-alkyl radical, R1 and R2, identical or different, each represent H or a C1-C10 hydrocarbon radical, R1 and R2 not both representing H, R3 represents a C1-C10 hydrocarbon radical, and R represents a phenyl radical monosubstituted or disubstituted by a substituent Y and, if applicable, a substituent Z, chosen from Cl, Br, I and CF3, or R represents a C?R4(R5) radical in which R4 represents an hydrocarbon radical and R5 represents a linear or branched, saturated or unsaturated, hydrocarbon radical, optionally substituted, a COR6 group or a CO2R6 group, where R6 represents a hydrogen atom or a linear or branched, saturated or unsaturated, hydrocarbon radical. This compound can be used for the treatment of higher plants for controlling their growth and architecture.

Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.

Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.

Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.